Cancer Biopsy Market By Product Type (Liquid Biopsy, Tissue Biopsy), By Application (Early Cancer Detection, Cancer Diagnosis, Prognostic Testing, Monitoring Treatment Response), By End-User Industry (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, Biopharmaceutical Companies), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cancer Biopsy Market was valued at USD 21.3 billion in 2023 and will surpass USD 41.6 billion by 2030; growing at a CAGR of 10.0% during 2024 - 2030. The cancer biopsy market is expanding rapidly due to the growing need for early detection and personalized treatment in oncology. With rising cancer prevalence worldwide, the demand for accurate diagnostic methods, such as liquid and tissue biopsies, is increasing. These biopsies allow healthcare providers to gather critical information about cancer, including its stage, genetic makeup, and response to treatment. Advancements in biopsy technologies have significantly improved the accuracy and efficiency of cancer detection, providing clinicians with tools to deliver better outcomes for patients. As the oncology field continues to evolve, the cancer biopsy market is expected to see further growth driven by technological innovations and increased healthcare investments. Product Type Segment is Largest Owing to the Dominance of Liquid Biopsy Liquid biopsy is currently the largest subsegment in the cancer biopsy market, owing to its non-invasive nature and ability to detect genetic mutations, biomarkers, and other cancer-related alterations through bodily fluids like blood or urine. Liquid biopsy is a breakthrough technology that provides a less invasive and more accessible option compared to traditional tissue biopsies, making it an attractive choice for both patients and healthcare providers. This type of biopsy is gaining traction in the market due to its ability to detect cancer at earlier stages, enabling better treatment options and improved survival rates. The growth of liquid biopsy can also be attributed to its potential for monitoring cancer progression or relapse through regular testing, which is not possible with tissue biopsies. This is particularly beneficial in monitoring treatment responses or evaluating the effectiveness of therapies in real-time. With continued advancements in genetic sequencing technologies and improvements in the sensitivity of liquid biopsy tests, the segment is poised for significant growth in the coming years, especially in the fields of personalized medicine and cancer surveillance. Application Segment is Fastest Growing Owing to Early Cancer Detection The early cancer detection application is the fastest-growing segment in the cancer biopsy market, driven by the increasing emphasis on diagnosing cancer at the earliest possible stage to improve patient outcomes. Early detection plays a critical role in reducing cancer mortality rates as treatments are more effective when the disease is identified before it spreads. Liquid and tissue biopsies are central to this effort, allowing for the identification of tumor markers and genetic mutations that signal the presence of cancer. As healthcare providers focus more on prevention and early intervention, the demand for early cancer detection solutions is surging. The growing awareness about the benefits of early diagnosis, combined with advancements in molecular diagnostics, is propelling the adoption of biopsy technologies. With the increasing use of biopsies in routine screening programs, this segment is expected to experience significant growth, especially as technologies become more refined, accurate, and accessible to a broader patient population. End-User Industry Segment is Largest in Hospitals Due to High Demand for Cancer Treatment Hospitals represent the largest end-user industry in the cancer biopsy market, primarily because of their capacity to treat large volumes of cancer patients and the essential role they play in the diagnosis and treatment of various cancers. Hospitals are equipped with specialized infrastructure and trained personnel to carry out biopsies, whether liquid or tissue-based, providing accurate and timely cancer diagnoses. The demand for biopsies in hospitals continues to grow as cancer rates rise, leading to more patients seeking diagnostic and therapeutic services. Hospitals also serve as critical hubs for cancer research and clinical trials, driving the adoption of advanced biopsy technologies. They are increasingly integrating cutting-edge tools such as next-generation sequencing (NGS) and liquid biopsy platforms to improve diagnostic accuracy and streamline patient management. As the healthcare system focuses more on precision medicine, hospitals are expected to remain a dominant force in the cancer biopsy market, supporting the growth of biopsy services and technologies. Cancer Type Segment is Largest in Lung Cancer Due to High Incidence and Advancements in Detection Technologies Lung cancer is the largest cancer type segment in the cancer biopsy market due to its high incidence rate and the advancements in biopsy technologies that have made it easier to detect early-stage lung cancer. Lung cancer, particularly non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide, which makes accurate and timely diagnosis essential. Biopsy tests, including liquid biopsies and tissue samples, are critical for detecting mutations and genetic markers that inform treatment decisions, such as targeted therapy and immunotherapy. The growing use of liquid biopsy in lung cancer detection has contributed to the market's expansion, as it offers a non-invasive method for obtaining genetic material from circulating tumor DNA (ctDNA) in blood samples. This approach allows for earlier detection, better monitoring of treatment response, and the identification of resistance mutations, enabling more tailored therapies. With the increasing focus on personalized medicine and improved diagnostic techniques, lung cancer remains a key area of development for cancer biopsy technologies. Fastest Growing Region is Asia Pacific Due to Increasing Cancer Incidence and Healthcare Advancements The Asia Pacific (APAC) region is the fastest-growing region in the cancer biopsy market. This growth can be attributed to the increasing incidence of cancer in countries like China, India, and Japan, along with improvements in healthcare infrastructure and the growing adoption of advanced diagnostic technologies. The region’s aging population and rising cancer awareness are contributing to the increased demand for accurate and early cancer detection methods, including biopsy technologies. As healthcare systems in APAC countries modernize and the availability of healthcare services expands, there is greater access to advanced diagnostic tools like liquid biopsy, which is being used in conjunction with traditional tissue biopsy methods. The growing biopharmaceutical industry in the region, alongside government support for cancer care, further propels the uptake of innovative biopsy technologies. With a large and diverse patient population, APAC is expected to continue leading the global cancer biopsy market's growth in the coming years. Leading Companies and Competitive Landscape The cancer biopsy market is highly competitive, with several global companies leading the charge in the development and commercialization of biopsy technologies. Major players in the market include Roche, Thermo Fisher Scientific, Illumina, Qiagen, Abbott Laboratories, Guardant Health, and Exact Sciences Corporation. These companies are focusing on expanding their product portfolios by offering advanced liquid biopsy platforms, next-generation sequencing technologies, and comprehensive diagnostic solutions for cancer detection and monitoring. The competitive landscape is shaped by the rapid advancement of molecular diagnostic technologies and the growing demand for personalized medicine. Key players are investing heavily in research and development to innovate and offer more accurate, cost-effective, and minimally invasive biopsy solutions. Additionally, partnerships, acquisitions, and collaborations with healthcare providers, research institutions, and biopharmaceutical companies are common strategies to expand market share and gain access to new technologies and markets. As the market continues to evolve, the emphasis on improving diagnostic precision and patient outcomes will intensify, making it crucial for companies to remain at the forefront of innovation in the cancer biopsy field. Recent Developments: • Roche announced the launch of its new liquid biopsy test, designed to detect early-stage lung cancer with higher sensitivity, offering a less invasive alternative to traditional biopsy methods. • Guardant Health received FDA approval for its Guardant360 test, a liquid biopsy technology that identifies genetic mutations in cancer patients, improving personalized treatment options and response monitoring. • Illumina partnered with Foundation Medicine to expand the availability of next-generation sequencing-based cancer testing, improving early diagnosis and treatment selection for various cancers. • Exact Sciences acquired a leading liquid biopsy company, enhancing its capabilities in non-invasive cancer detection and solidifying its position in the early cancer diagnostics market. • Qiagen received regulatory approval for its new PCR-based biopsy test, designed to detect specific genetic mutations associated with colorectal cancer, helping clinicians make more informed treatment decisions. List of Leading Companies: • Roche • Thermo Fisher Scientific • Illumina • Bio-Rad Laboratories • Abbott Laboratories • Qiagen • Guardant Health • Exact Sciences Corporation • Foundation Medicine • Veracyte • Neogenomics • Siemens Healthineers • GE Healthcare • Philips Healthcare • Agilent Technologies Report Scope: Report Features Description Market Size (2023) USD 21.3 Billion Forecasted Value (2030) USD 41.6 Billion CAGR (2024 – 2030) 10.0% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Cancer Biopsy Market By Product Type (Liquid Biopsy, Tissue Biopsy), By Application (Early Cancer Detection, Cancer Diagnosis, Prognostic Testing, Monitoring Treatment Response), By End-User Industry (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, Biopharmaceutical Companies), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Roche, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Guardant Health, Exact Sciences Corporation, Foundation Medicine, Veracyte, Neogenomics, Siemens Healthineers, GE Healthcare, Philips Healthcare, Agilent Technologies Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements